文献速递哮喘呼吸道感染

吸入伊曲康唑治疗哮喘合并变应性支气管肺曲霉病的2期随机对照试验

Safety and efficacy of inhaled itraconazole in adults with asthma and allergic bronchopulmonary aspergillosis (PUR1900-ABPA): a randomized, double-blind, parallel group, placebo-controlled, multicenter, phase 2 trial.
PubMed 文献 · Eur Respir J · 2026-07-16

PUR1900-ABPA是一项2期、多中心、随机、双盲、平行组、安慰剂对照试验,纳入43例哮喘合并ABPA成人,按2:2:1随机接受吸入PUR1900 20 mg、40 mg或安慰剂每日一次治疗16周。

要点

  • 吸入PUR1900 40 mg每日一次治疗16周可改善ABPA患者FEV1和ACQ-7。
  • 20 mg组未观察到安慰剂校正效应,40 mg组不良事件发生率31%且无严重事件。

核心结论

  • PUR1900 40 mg在ABPA关键临床域中与改善相关,安全性良好,支持进一步开展3期评价。

研究设计与样本

  • 2期、多中心、随机、双盲、平行组、安慰剂对照试验,43例哮喘合并ABPA成人按2:2:1随机分组。
  • 受试者接受吸入PUR1900 20 mg、40 mg或安慰剂每日一次治疗16周。
  • 关键入组标准包括血清总IgE≥1000 kU·L-1、ACQ-7评分>1.5、支气管舒张剂前FEV1占预计值50-85%。
  • 研究无预设主要终点,评估肺功能、免疫学及患者报告等多个探索性结局。

主要发现

  • 第16周时,PUR1900 40 mg组FEV1较安慰剂校正改善LSM +0.28 L(95%CI 0.02,0.53)。
  • 第16周时,PUR1900 40 mg组ACQ-7较安慰剂校正改善LSM -0.51分(95%CI -0.97,-0.06)。
  • PUR1900 20 mg组未观察到安慰剂校正效应。
  • 不良事件发生率在40 mg组为31%、20 mg组为39%、安慰剂组为44%,均无严重不良事件。

临床怎么用

  • 对于哮喘合并ABPA成人,吸入PUR1900 40 mg每日一次治疗16周可能改善肺功能和哮喘控制并降低总IgE。
  • 治疗前需确认血清总IgE≥1000 kU·L-1、ACQ-7>1.5且FEV1占预计值50-85%等入组条件。
  • 20 mg剂量未显示安慰剂校正效应,临床决策应关注40 mg剂量证据。

局限性

  • 研究无预设主要终点,多个探索性结局需谨慎解读。
  • 样本量较小(共43例),研究周期为16周。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: No therapies are approved for allergic bronchopulmonary aspergillosis (ABPA), which affects an estimated 4.8 million asthmatic individuals worldwide. Current treatment with oral corticosteroids or oral itraconazole is limited by systemic toxicities, drug-drug interactions, and suboptimal airway drug concentrations. PUR1900 is a novel inhaled itraconazole formulation designed to achieve high airway concentrations with minimal systemic exposure. METHODS: We conducted a phase 2, multicenter, randomized, double-blind, parallel-group, placebo-controlled trial. Adults with asthma and ABPA were randomized (2:2:1) to receive inhaled PUR1900 20 mg, PUR1900 40 mg, or placebo once daily for 16 weeks. Key eligibility criteria included serum total IgE ≥1000 kU·L-1, Asthma Control Questionnaire (ACQ)-7 score >1.5, and pre-bronchodilator FEV1 50-85% predicted. The study had no prespecified primary endpoint and evaluated multiple exploratory outcomes across lung function, immunological, and patient-reported domains. RESULTS: We randomized 43 participants (20 mg, n=18; 40 mg, n=16; placebo, n=9); 39 completed treatment. Baseline characteristics were balanced. At week 16, PUR1900 40 mg was associated with placebo-adjusted improvements in FEV1 (LSM +0.28 L; 95% CI: 0.02, 0.53) and ACQ-7 (LSM -0.51 points; 95% CI: -0.97, -0.06), with reductions in serum total IgE (LSM -2619 kU·L-1; 95% CI: -5342, 105). No placebo-adjusted effects were observed with PUR1900 20 mg. Adverse events occurred in 31%, 39%, and 44% of participants receiving 40 mg, 20 mg, and placebo, respectively; none were serious. CONCLUSIONS: PUR1900 40 mg was associated with improvements across key clinical domains in ABPA, with a favorable safety profile, supporting further phase 3 evaluation.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Agarwal R, Chaudhary D, Gupta SN, et al. Safety and efficacy of inhaled itraconazole in adults with asthma and allergic bronchopulmonary aspergillosis (PUR1900-ABPA): a randomized, double-blind, parallel group, placebo-controlled, multicenter, phase 2 trial. Eur Respir J. 2026. PMID: 42463270. doi:10.1183/13993003.00058-2026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。